Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Post by Baggiedoug1on Aug 21, 2017 9:09am
212 Views
Post# 26602372

Great News

Great News
Ventripoint Reports on Use of VMS Heart Analysis System to Reliably Measure Remodeling of the Right Ventricle TORONTO, ONTARIO--(Marketwired - Aug. 21, 2017) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE:VPT) announces that the cardiology group at Royal Free Hospital in London, UK has published a study entitled "Two-dimensional knowledge-based volumetric reconstruction of the right ventricle documents short-term improvement in pulmonary hypertension" in Echocardiography, volume 34, pages 817-824. This study confirms the ability of the VMS Heart Analysis System (referred to in the paper as "two-dimensional knowledge-based volumetric reconstruction or 2DKBR) to follow patients with enlarged right ventricles (RV) and accurately measure small but medically-significant changes in volume and function. This ability to monitor clinical outcomes shortly after the initiation of therapy is important to determine if the therapy is working well or if a new therapeutic approach is required. The VMS detected the remodeling of the RV to reduce its size in patients who improved and an increase in RV size in patients with worse clinical outcomes including death. "Ventricular remodeling in PAH can be differentiated into two patterns: adaptive remodeling with concentric hypertrophy and preserved function, and maladaptive remodeling with eccentric hypertrophy and worsening function. Our study shows that within several months a change from one pattern to the other can occur with medical therapy," stated the authors. The group concluded; "2DKBR can be reliably used in a busy clinical setting to follow-up right-ventricular indices in pulmonary hypertension"
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse